Sign up to save your podcasts
Or
Share ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
More shows like Neurology Today in 5
View all
JAMA Editors' Summary
132 Listeners
Global News Podcast
7,693 Listeners
Neurology® Podcast
285 Listeners
NEJM This Week
322 Listeners
Practical Neurology Podcast
45 Listeners
JAMA Clinical Reviews
496 Listeners
JAMA Neurology Author Interviews
14 Listeners
Annals On Call Podcast
186 Listeners
The Clinical Problem Solvers
514 Listeners
Neurology Minute
132 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Neurology Exam Prep Podcast
182 Listeners
The Curious Clinicians
363 Listeners
The Lancet Neurology in conversation with
2 Listeners
Continuum Audio
77 Listeners